Methicillin-resistant Staphylococcus aureus (MRSA)

Overview 
Theory 
Diagnosis 
Management 
Follow up 
Resources 

Brilacidin

Brilacidin belongs to a new class of antibiotics called peptide mimetics, or defensin mimetics.[54] It is being developed as a single-dose drug, with activity against gram-positives and gram-negatives, including resistant organisms such as MRSA and has completed phase 2 studies.

Ceftobiprole

Ceftobiprole is an intravenous cephalosporin and the first beta-lactam antibiotic to have activity against MRSA.[55]

Iclaprim

Iclaprim is a diaminopyrimidine that inhibits dihydrofolate reductase. Preliminary results from trials have shown activity against MRSA.[51][56]

Faropenem

Faropenem is a carbapenem given orally for skin infections. It has in vitro activity against MRSA.[51][56]

Fosfomycin

Clinical data show that fosfomycin, primarily in combination regimens, has been associated with clinical success in 28/29 (96.6%) cases of infection (mainly pneumonia, bacteremia, and meningitis) by fosfomycin-susceptible isolates of methicillin-resistant Staphylococcus aureus. Further research is needed to establish the role of fosfomycin against infections caused by gram-positive cocci with advanced antimicrobial drug resistance.[57]

Use of this content is subject to our disclaimer